ReviewMammalian genome : official journal of the International Mammalian Genome Society2018
Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer.
Review in Mammalian genome : official journal of the International Mammalian Genome Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 38 citations in OpenAlex.
- PVR Mediates Resistance to IL21.CD276.CAR-T Therapy in Esophageal Squamous Cell Carcinoma.International journal of molecular sciences · 2026Article
- TIGIT Blockade Potentiates the Anti-Leukemic Activity of Exercise-Mobilized Donor Lymphocytes and Expanded γδ T-Cells.Cancers · 2026Article
- Colocalization analysis of 3' UTR alternative polyadenylation quantitative trait loci reveals novel mechanisms underlying associations with lung function.Human molecular genetics · 2024Article
- Single-cell and spatial transcriptome characterize coinhibitory cell-cell communications during histological progression of lung adenocarcinoma.Frontiers in immunology · 2024Article
- Current Approaches of Immune Checkpoint Therapy in Chronic Lymphocytic Leukemia.Current treatment options in oncology · 2023Review
- Tumor-infiltrating CD226Journal of cancer research and clinical oncology · 2023Article
- Immunotherapy in leukaemia.Acta biochimica et biophysica Sinica · 2023Review
- Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer.Frontiers in oncology · 2023Article
- Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy.Pharmacological reviews · 2022Review
- Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications.Nature communications · 2022Article
- Identification of therapeutic targets for osteosarcoma by integrating single-cell RNA sequencing and network pharmacology.Frontiers in pharmacology · 2022Article
- Review
- CD96 Downregulation Promotes the Immune Response of CD4 T Cells and Associates with Ankylosing Spondylitis.BioMed research international · 2022Article
- Deoxythymidylate Kinase as a Promising Marker for Predicting Prognosis and Immune Cell Infiltration of Pan-cancer.Frontiers in molecular biosciences · 2022Article
- Prostate cancer-associated urinary proteomes differ before and after prostatectomy.Therapeutic advances in medical oncology · 2022Article
- Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer.Frontiers in immunology · 2022Article
- The CD112R/CD112 axis: a breakthrough in cancer immunotherapy.Journal of experimental & clinical cancer research : CR · 2021Review
- Natural Killer Cells in the Malignant Niche of Multiple Myeloma.Frontiers in immunology · 2021Review
- TIGIT Induces (CD3+) T Cell Dysfunction in Colorectal Cancer by Inhibiting Glucose Metabolism.Frontiers in immunology · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Avoiding immune surveillance and inducing a tumor-promoting inflammatory milieu found entry into the new generation of the hallmarks of cancer. Cancer cells hijack immune mechanisms which physiologically protect the body from the development of autoimmune diseases and excessive tissue damage during inflammation by downregulating immune responses. This is frequently achieved by upregulation of immune checkpoints. Therefore, the blocking of immune checkpoint ligand-receptor interactions can reinstall the immune systems capability to fight cancer cells as shown for CTLA4 and PD-1 inhibitors in a clinical setting. Newly described checkpoint antigens are currently under investigation in cancer immunotherapy. Preclinical data emphasize the immune checkpoint axis TIGIT-PVR/PVRL2 as very promising target. This axis includes additional receptors such as DNAM-1, CD96, and CD112R. In this review, we discuss the recent findings of the relevance of this complex receptor ligand system in hematologic and solid cancers. Emphasis is also laid on the discussion of potential combinations with other immunotherapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.